Report Contents
Market Overview
The global Blood Collection market now delivers roughly USD 15.20 billion in revenue, driven by surging diagnostic workloads and expanding hospital networks. A 6.30 % CAGR forecast for 2026–2032 signals sustained momentum, urging leadership teams to reassess product pipelines and investment priorities.
Momentum accelerates as decentralized clinical trials demand mobile sampling kits, precision medicine raises specimen-quality standards, and emerging economies invest heavily in modern blood banking infrastructure. These converging trends broaden the market’s scope and reshape competitive boundaries, rewarding enterprises that scale efficiently and localize offerings through robust technological integration.
This report transforms the shifting landscape into concise, actionable intelligence for manufacturers, distributors and institutional buyers. It benchmarks automation roadmaps, regional supply-chain models and digital connectivity investments critical to defending margin and market share. Leaders will find essential guidance for navigating disruption, seizing emergent opportunities and crafting resilient strategies through 2032.
Market Growth Timeline (USD Billion)
Source: Secondary Information and ReportMines Research Team - 2026
Market Segmentation
The Blood Collection Market analysis has been structured and segmented according to type, application, geographic region and key competitors to provide a comprehensive view of the industry landscape.
Key Product Application Covered
Key Product Types Covered
Key Companies Covered
By Type
The Global Blood Collection Market is primarily segmented into several key types, each designed to address specific operational demands and performance criteria.
-
Blood Collection Tubes:
Blood collection tubes retain the largest revenue share because they are indispensable for preserving specimen integrity across chemistry, hematology and molecular assays. Most hospital laboratories purchase tubes in bulk, driving economies of scale and keeping average unit costs below USD 0.12.
Advances in vacuum precision have pushed draw accuracy to nearly 98.00%, reducing pre-analytical error rates and reinforcing the product’s competitive edge over manual open-top vials. Manufacturers offering integrated gel separators report up to 22.00% faster centrifugation workflows, allowing high-throughput labs to process more than 3,600 samples per hour.
Growth is primarily fueled by the increasing adoption of automated analyzer lines that require standardized tube dimensions and bar-coding. As national health systems mandate traceable specimen management, demand for premium evacuated tubes with RFID labels is expected to surge.
-
Blood Collection Needles and Syringes:
Needles and syringes command a stable, high-volume position due to their use in both inpatient phlebotomy and outpatient point-of-care testing. Safety-engineered variants now account for a significant portion of sales as facilities aim to cut needlestick incidents below the OSHA target of 0.50 cases per 100 full-time workers.
Retractable mechanisms have improved post-draw safety compliance to 96.00%, a 14.00% uplift over traditional fixed needles, delivering a tangible competitive advantage. Simultaneously, thin-wall cannula designs enable up to 25.00% higher flow rates, shortening venipuncture time and improving patient comfort.
Regulatory requirements such as the EU Sharps Directive continue to drive rapid replacement cycles, while rising vaccination programs in emerging markets are expanding the addressable volume base at a compound annual rate above the sector average.
-
Lancets:
Lancets occupy a specialized niche focused on capillary sampling for glucose monitoring, neonatal testing and coagulation screens. Single-use, auto-retractable models have reduced cross-contamination risk to below 0.10%, cementing their relevance in diabetic care pathways.
Ergonomic trigger designs now enable penetration depths as low as 0.80 mm while maintaining sufficient blood volume, decreasing perceived pain scores by 30.00% compared with legacy spring models. This user-centric advantage supports strong loyalty in home-care channels.
Market expansion is driven by the sharp growth in self-monitoring blood glucose meters—shipments of which surpassed 110,000,000 units globally last year—creating continuous demand for compatible lancet refills.
-
Blood Collection Sets:
Butterfly blood collection sets are preferred for geriatric, pediatric and oncology patients with fragile veins. Their flexible tubing and winged needles can cut hemolysis rates by 45.00% compared with straight-needle alternatives, safeguarding sample validity.
By integrating pre-attached Luer adapters, premium sets enable seamless connection to evacuated tubes or syringes, saving up to 18.00 seconds per draw in high-volume outpatient clinics—a meaningful productivity gain that underpins their competitive edge.
Demand is accelerating as infusion centers proliferate and home-based chemotherapy protocols rise, both scenarios requiring gentle venous access solutions and bolstering recurring procurement contracts.
-
Blood Bags:
Blood bags remain mission-critical in transfusion medicine, with the quadruple-bag configuration supporting component separation for red cells, plasma, platelets and cryoprecipitate. Adoption of DEHP-free plastics has reduced leachate levels by 65.00%, meeting stringent biocompatibility standards.
In-line leukoreduction filters now integrated in over 70.00% of bags can remove up to 99.99% of white cells, extending shelf life and improving transfusion safety—an attribute that differentiates premium suppliers from low-cost entrants.
The principal growth catalyst is the rising volume of elective surgeries in Asia-Pacific, which climbed 8.20% year on year, compelling blood centers to upgrade inventories and favor multi-chamber, high-yield bag systems.
-
Capillary Blood Collection Devices:
Micro-collection vessels tailored for pediatric and remote diagnostic applications are gaining traction as decentralized testing expands. Their small 300 µL capacity minimizes iatrogenic anemia risks, a critical advantage in neonatal intensive care units.
Pre-coated anticoagulant interiors ensure clot-free stability for up to 72 hours, extending transport windows by 50.00% over uncoated glass capillaries and facilitating regional reference-lab consolidation.
Growth momentum stems from the proliferation of at-home test kits and telemedicine platforms that rely on finger-stick sampling, prompting diagnostics firms to form strategic alliances with capillary device manufacturers.
-
Accessories and Ancillary Supplies:
This category encompasses tourniquets, alcohol swabs, gauze and labeling systems—items that, while low in individual value, collectively account for a consistent replenishment revenue stream. Automated labeling guns can reduce specimen ID errors by 93.00%, highlighting their operational importance.
Silicone tourniquets offer 40.00% higher elasticity retention after 100 autoclave cycles compared with latex, giving suppliers a durability-based competitive advantage at ambulatory surgery centers.
Hospital consolidation is elevating demand for bundled procurement contracts, encouraging accessory vendors to integrate RFID tag solutions with swabs and labels to support enterprise-wide traceability initiatives.
Market By Region
The global Blood Collection market demonstrates distinct regional dynamics, with performance and growth potential varying significantly across the world's major economic zones.
The analysis will cover the following key regions: North America, Europe, Asia-Pacific, Japan, Korea, China, USA.
-
North America:
North America maintains strategic relevance because it houses robust healthcare infrastructure, sophisticated transfusion services and major device manufacturers. Canada’s publicly funded health system and Mexico’s expanding private hospital chains collectively sustain steady procurement, while cross-border clinical trial activity keeps demand predictable.
The region is estimated to hold a sizeable share of global revenue, driven largely by replacement demand for safety-engineered needles. Untapped potential lies in rural Mexico where donor recruitment lags, yet logistics challenges, limited cold-chain capacity and fragmented reimbursement systems must be resolved to unlock meaningful volume growth.
-
Europe:
Europe’s market significance stems from stringent regulatory frameworks that push early adoption of closed-system vacutainers and pathogen-reduction technologies. Germany, France and the United Kingdom lead purchasing due to centralized blood services and ongoing modernization of phlebotomy centers.
Although the region offers a mature, stable revenue base, Eastern European nations still exhibit underpenetration, representing growth pockets. Harmonizing post-Brexit device approvals, navigating divergent reimbursement codes and addressing persistent donor shortages in Southern Europe are critical challenges that determine the pace of expansion.
-
Asia-Pacific:
The broader Asia-Pacific bloc functions as a high-growth engine owing to rapid healthcare investment and rising surgical volumes. India, Australia and Southeast Asian members of ASEAN spearhead uptake, buoyed by government immunization drives and the proliferation of private diagnostic chains.
The region’s contribution to global sales is rapidly climbing from a modest base, yet vast rural populations remain underserved. Opportunities include mobile blood banks and low-cost micro-collection devices, but progress hinges on overcoming fragmented regulatory pathways, limited donor education and intermittent power supply that jeopardizes sample integrity.
-
Japan:
Japan commands strategic influence through advanced automation, a strong culture of preventative testing and early integration of robotics into blood collection rooms. National health insurance coverage promotes routine draws, keeping domestic demand resilient even during broader economic cycles.
Market share is steady rather than explosive, with growth primarily linked to replacement cycles for high-precision vacuum tubes. Unlocking new revenue depends on penetrating smaller prefecture clinics and integrating digital barcoding, yet manufacturers must navigate strict pharmacovigilance rules and an aging phlebotomy workforce.
-
Korea:
South Korea’s market profile is characterized by aggressive adoption of next-generation safety lancets and smart collection carts in tertiary hospitals. Government initiatives aimed at becoming a regional medical tourism hub further bolster procedure volumes and consumable consumption.
While Seoul and Busan drive most sales, mid-tier cities still display latent demand. Expansion opportunities revolve around point-of-care micro-sampling for telehealth, but suppliers must tackle compressed hospital budgets, competitive domestic OEMs and high expectations for rapid regulatory clearance.
-
China:
China holds formidable strategic weight, accounting for a significant portion of global incremental revenue as urbanization, oncology screening and health-check programs escalate phlebotomy volumes. Tier-one cities such as Shanghai and Beijing currently dominate expenditure through centralized procurement platforms.
Untapped upside resides in lower-tier cities where blood safety initiatives are only now scaling. Companies that localize production to meet new national standard GB9706 can gain share, though they must contend with price-controlled tenders, diverse provincial policies and fluctuating donor mobilization after pandemic-induced disruptions.
-
USA:
The United States remains the single largest national market, benefiting from advanced hospital networks, a vibrant clinical research ecosystem and early deployment of pathogen-reduction additive solutions. Continuous technical upgrades and the push toward precision medicine sustain elevated demand for high-integrity sample collection.
Despite its mature status, substantial opportunity exists in ambulatory surgery centers and at-home phlebotomy services. However, reimbursement pressure from private payers, intermittent shortages of trained phlebotomists and varying state-level regulatory nuances can constrain supplier growth if unaddressed.
Market By Company
The Blood Collection market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.
-
Becton, Dickinson and Company:
Becton, Dickinson and Company (BD) commands a long-standing leadership position in venipuncture needles, evacuated tube systems, and blood collection sets. Its global distribution network and broad product portfolio allow it to set quality benchmarks that many hospitals and diagnostic labs treat as default purchasing standards.
In 2025, BD is projected to generate USD 2.74 Billion from blood collection products, translating into a dominant 18.00% share of the worldwide market. These figures highlight BD’s ability to capture premium pricing through continuous improvements in needle-shield safety technology and integrated specimen management software.
BD’s competitive differentiation stems from end-to-end automation capabilities that link its Vacutainer lines with hospital information systems, reducing pre-analytical errors. Coupled with high switching costs for health systems already standardized on BD consumables, this integration keeps emerging rivals at bay.
-
Terumo Corporation:
Terumo leverages its Japanese manufacturing excellence to produce high-precision hypodermic and apheresis devices. The company’s catheter know-how gives it unique insight into fluid dynamics, enabling low-hemolysis blood collection kits that are favored for oncology and critical care applications.
For 2025, Terumo’s blood collection revenue is expected to reach USD 1.52 Billion, equal to a solid 10.00% market share. The scale demonstrates Terumo’s success in bundling its Teresapher apheresis platform with consumables, creating a recurring revenue stream that cushions commodity price swings.
Strategically, Terumo differentiates by marrying disposable collection sets with real-time data analytics that help blood banks optimize donor scheduling. This digital layer positions the firm as a partner rather than just a supplier.
-
Greiner Bio-One International GmbH:
Greiner Bio-One centers its competitive edge on premium polymer technology, offering evacuated tubes with low additive variability. European clinical labs rely on its VACUETTE tubes to meet stringent ISO 15189 accreditation standards, reinforcing the brand’s reputation for analytical accuracy.
The company’s 2025 revenue is projected at USD 1.06 Billion, corresponding to a respectable 7.00% global share. This share underscores Greiner’s ability to win tenders in public health systems that place heavy emphasis on traceability and barcode integration.
Greiner’s modular production lines allow fast color-coding changes for region-specific anticoagulant requirements, an operational agility that larger competitors sometimes lack.
-
Fresenius Kabi AG:
Fresenius Kabi applies its infusion therapy expertise to blood collection, particularly in sterile fluid pathways and closed-loop systems. Hospitals appreciate its single-vendor proposition that covers collection, processing, and transfusion disposables.
With projected 2025 sales of USD 0.91 Billion and a 6.00% share, Fresenius Kabi maintains mid-tier scale but high strategic relevance. Its focus on plasma fractionation compatibility aligns well with the rising demand for immunoglobulins.
The firm’s competitive moat lies in vertically integrated production from raw polymers to sterilization, ensuring supply security that many hospital groups now prioritize after recent pandemic-induced shortages.
-
Nipro Corporation:
Nipro leverages decades of dialysis tubing experience to manufacture kink-resistant blood collection needles and connectors. The company’s strength lies in cost-effective manufacturing, enabling aggressive pricing in emerging markets without compromising product integrity.
In 2025, Nipro is expected to post USD 0.76 Billion in revenue, capturing a 5.00% share of the global market. This footprint reflects its successful channel partnerships across Southeast Asia and Latin America.
Nipro differentiates through localized training programs that teach phlebotomists best-practice needle angles, lowering sample rejection rates and fostering loyalty to its brand.
-
Haemonetics Corporation:
Haemonetics is synonymous with advanced apheresis and blood component technologies. Its NexSys PCS platform for plasma collection has reshaped donation center economics by boosting yield per donor session.
The firm’s 2025 blood collection revenue is projected to be USD 0.76 Billion, identical to Nipro’s figure yet translating into a 5.00% share driven more by high-value disposables than by volume.
A clear strategic advantage is Haemonetics’ software suite that aggregates donor data into predictive maintenance and regulatory compliance dashboards, creating a sticky ecosystem around its hardware.
-
SARSTEDT AG and Co. KG:
SARSTEDT capitalizes on German engineering to produce precisely molded blood collection tubes with leak-proof screw caps favored for pediatric sampling. Its family-owned structure allows rapid reinvestment into niche innovations without shareholder pressure.
Expected 2025 revenue stands at USD 0.61 Billion, translating into a 4.00% share of the market. Although smaller than BD or Terumo, SARSTEDT’s focus on specialized segments yields healthy margins.
By offering color-coded micro-collection systems that integrate seamlessly with automated hematology analyzers, the firm maintains a loyal user base in neonatal units worldwide.
-
Macopharma:
French manufacturer Macopharma specializes in blood bag systems with integrated leukocyte filtration, supporting transfusion services that aim to reduce transfusion-related immunomodulation.
The company is projected to record USD 0.61 Billion in 2025, securing a 4.00% global share. Its revenue concentration in Europe and North Africa demonstrates the strength of regional sourcing strategies.
Macopharma’s competitive edge lies in additive solution expertise that extends red cell shelf life to forty-two days, a compelling value proposition for national blood services striving to minimize discard rates.
-
FL MEDICAL s.r.l.:
FL MEDICAL, an Italy-based SME, targets mid-range laboratories with cost-efficient evacuated tubes and ergonomic collection needles. Its lean manufacturing processes enable quick turnaround on private-label orders for regional distributors.
With 2025 revenues forecast at USD 0.46 Billion and a 3.00% share, the company occupies a niche position but punches above its weight in customer customization.
The firm’s small-batch flexibility and willingness to develop country-specific anticoagulant blends differentiate it from more rigid multinationals.
-
Kawasumi Laboratories Inc.:
Kawasumi brings specialized polymer extrusion techniques to blood collection sets, emphasizing biocompatibility and low endotoxin levels—attributes prized by Japanese and U.S. transplant centers.
Its 2025 revenue is anticipated at USD 0.46 Billion, equating to a 3.00% slice of the market. While modest, this scale supports heavy reinvestment in R&D relative to sales.
The firm’s strategic distinction lies in co-developing devices with academic hospitals, ensuring early adoption of next-generation blood bags featuring ultraviolet pathogen inactivation windows.
-
Grifols S.A.:
Grifols leverages its vertically integrated plasma business to supply blood collection systems optimized for downstream fractionation. The company’s expertise in cold-chain logistics ensures minimal protein degradation from vein to processing plant.
In 2025, Grifols’ blood collection segment is set to earn USD 0.91 Billion, accounting for 6.00% of global sales. This share mirrors its dual role as both device manufacturer and plasma therapeutics producer.
A key competitive advantage is Grifols’ proprietary barcode architecture that tracks plasma from donor to final immunoglobulin vial, meeting increasingly strict regulatory traceability mandates.
-
JMS Co., Ltd.:
JMS combines expertise in infusion pumps with disposable blood collection kits tailored for operating rooms and acute care settings. Its products are known for high flow accuracy, reducing sampling time during critical interventions.
The company is projected to secure USD 0.46 Billion in 2025 revenue, capturing a 3.00% market share. Although niche, this presence grants JMS leverage to negotiate bundled procurement contracts alongside its infusion devices.
JMS differentiates via proprietary silicone coatings that lessen patient discomfort, a feature often highlighted in tenders for pediatric and geriatric wards.
-
Cardinal Health, Inc.:
Cardinal Health leverages its vast U.S. distribution network to supply a broad slate of private-label tubes and needles, enabling hospitals to standardize procurement while containing costs. The company’s logistics infrastructure ensures next-day delivery to nearly every American metro area.
Expected 2025 revenue from blood collection products is USD 1.06 Billion, equal to a 7.00% share of the global market. This scale demonstrates Cardinal’s strength in contract manufacturing and branded resale.
The strategic advantage revolves around volume-driven price negotiation and bundled purchasing agreements that tie consumables to its broader medical-surgical catalog, effectively locking in customers through convenience and cost savings.
-
Medline Industries, LP:
Medline, a privately held U.S. powerhouse, utilizes deep relationships with integrated delivery networks to push its VACU-Guard needle safety systems. By investing heavily in on-site inventory management programs, Medline minimizes stock-outs for its clients.
The firm is anticipated to generate USD 0.91 Billion in 2025, claiming a 6.00% market share. This revenue signals Medline’s strength in capturing mid-tier and community hospital demand that larger peers sometimes overlook.
Medline’s key differentiator is its integrated consulting arm that assists hospitals in optimizing phlebotomy workflows, creating stickiness that pure-play manufacturers struggle to match.
-
Quest Diagnostics Incorporated:
Quest Diagnostics occupies a unique dual role as both a diagnostic services provider and a developer of specialized blood collection kits designed to preserve biomarkers during transport to its labs. The kits incorporate proprietary stabilizing reagents that align with Quest’s high-throughput testing pipelines.
For 2025, Quest’s kit and consumable sales are projected at USD 1.22 Billion, translating into an 8.00% share of the global blood collection market. This scale underlines how vertical integration from sample draw to result reporting can capture significant market value.
Quest’s differentiation centers on diagnostic-specific collection devices—for example, tubes formulated for next-generation sequencing panels—offering clinicians a one-stop solution that combines accurate draws with rapid lab analytics.
Key Companies Covered
Becton, Dickinson and Company
Terumo Corporation
Greiner Bio-One International GmbH
Fresenius Kabi AG
Nipro Corporation
Haemonetics Corporation
SARSTEDT AG and Co. KG
Macopharma
FL MEDICAL s.r.l.
Kawasumi Laboratories Inc.
Grifols S.A.
JMS Co., Ltd.
Cardinal Health, Inc.
Medline Industries, LP
Quest Diagnostics Incorporated
Market By Application
The Global Blood Collection Market is segmented by several key applications, each delivering distinct operational outcomes for specific industries.
-
Diagnostic Testing:
Diagnostic laboratories rely on blood collection to deliver definitive results for infectious disease screening, metabolic panels and genetic assays. The application commands the largest revenue contribution because every inpatient admission typically triggers at least three venous draws, underscoring its entrenched clinical significance.
Automated pre-analytical lines linked to high-throughput analyzers have shortened sample-to-result turnaround times by 28.00%, improving clinician decision cycles and lowering average length of stay. This operational advantage over slower biopsy-based methods drives consistent hospital investment despite budget constraints.
Growth is propelled by rising chronic disease prevalence and national mandates that require annual lipid and HbA1c testing, particularly in economies where preventive care incentives are tied to insurance reimbursements.
-
Therapeutic Transfusion:
Therapeutic transfusion focuses on restoring blood volume and correcting component deficiencies during surgery, trauma care and oncology treatment. Hospitals measure success by reduced perioperative mortality, which can improve by up to 15.00% when evidence-based transfusion protocols are employed.
Adoption remains high because modern blood typing and cross-matching systems cut incompatibility reaction rates below 0.20%, a substantial improvement over manual serology methods. This reliability justifies the inventory costs associated with maintaining diverse blood group supplies.
The primary catalyst for continued expansion is the aging global population, which is elevating demand for orthopedic and cardiac surgeries projected to rise 6.50% annually, thereby increasing transfusion volumes in both developed and emerging regions.
-
Blood Component Collection and Processing:
This application encompasses apheresis and fractionation workflows that separate whole blood into packed red cells, plasma, platelets and cryoprecipitate. Componentization maximizes resource utilization by enabling a single donation to benefit up to three patients, a compelling efficiency metric in constrained blood supply environments.
State-of-the-art apheresis devices now achieve plasma extraction efficiencies exceeding 85.00%, reducing donor time in chair by nearly 20.00% compared with first-generation systems. Such gains improve donor retention and lower per-unit collection costs.
The segment’s momentum stems from heightened demand for plasma-derived therapies and wider implementation of pathogen-reduction technologies, both of which push blood centers to upgrade processing capabilities to meet stringent quality benchmarks.
-
Clinical Research and Clinical Trials:
Pharmaceutical sponsors and contract research organizations depend on standardized blood collection to generate pharmacokinetic and biomarker data that underpin regulatory submissions. Consistent sample integrity can shorten protocol timelines by 10.00%, translating into multimillion-dollar earlier market entries for novel therapeutics.
Specialized collection kits with pre-labeled barcodes and temperature-stabilizing media differentiate this application from routine phlebotomy by ensuring chain-of-custody compliance across multi-center trials. These kits lower sample rejection rates to under 2.00%, saving considerable resampling costs.
Expansion is driven by the surge in decentralized and adaptive trial designs, where remote phlebotomy networks and mobile phlebotomists are indispensable for recruiting diverse patient populations and meeting enrollment milestones.
-
Point-of-Care Testing:
Point-of-care testing (POCT) leverages compact analyzers and micro-volume collection to provide near-instant results in emergency departments, ambulances and outpatient clinics. By delivering critical parameters such as troponin or lactate within 15 minutes, POCT can cut emergency triage time by 35.00% compared with central lab workflows.
Its distinct operational value lies in decentralized decision-making, reducing crowding and enabling earlier therapeutic intervention. Disposable cartridges integrated with capillary collection reduce contamination risk to below 0.50%, further enhancing clinical confidence.
Technological miniaturization and growing investment in connected diagnostics platforms are accelerating deployment, particularly in resource-limited settings seeking to meet World Health Organization recommendations for rapid disease detection.
-
Home Healthcare and Self-Collection:
Home healthcare and self-collection applications empower patients to monitor chronic conditions such as diabetes, anticoagulation status and hormonal levels without visiting clinical facilities. This autonomy can lower follow-up appointment frequency by 22.00%, reducing payer expenditures and improving patient satisfaction scores.
User-friendly lancet-plus-microtube kits paired with app-enabled shipping labels ensure specimens remain viable for up to 72 hours, supporting remote physician review and timely therapeutic adjustments. The convenience offered significantly differentiates this application from traditional site-based phlebotomy.
Adoption is rapidly advancing due to telehealth reimbursement expansions and consumer preference for at-home services. Public health emergencies have further accelerated regulatory approvals for mailed specimen kits, positioning this segment for sustained double-digit growth.
Key Applications Covered
Diagnostic Testing
Therapeutic Transfusion
Blood Component Collection and Processing
Clinical Research and Clinical Trials
Point-of-Care Testing
Home Healthcare and Self-Collection
Mergers and Acquisitions
Over the past twenty-four months, the Blood Collection Market has experienced a wave of acquisitions as leading device manufacturers and distributors jostle for technologies that reduce donor discomfort, automate laboratory workflows, and secure global supply continuity. Intensifying regulatory scrutiny, rising procedure volumes, and pandemic-driven supply shocks have heightened the strategic importance of vertical integration, prompting both multinational giants and specialized innovators to pursue focused, capability-enhancing deals rather than scale plays.
Major M&A Transactions
BD – Velano
Secure needle-free inpatient blood draw leadership
Terumo – EryPharm
Capture closed-system collection bag manufacturing capacity
Haemonetics – OpSens
Acquire fiber-optic sensors enhancing apheresis precision
Greiner – NanoporeDx
Access microfluidic capillary tubes enabling automation
FreseniusKabi – PlateletTech
Expand single-use platelet collection kit portfolio
CardinalHealth – Gentige
Strengthen hospital distribution for vacutainer consumables
Qiagen – NeuMoDx
Integrate high-throughput sample prep enhancing assays
BioRad – DropLabs
Obtain micro-drop digital PCR for screening
Consolidation is materially altering bargaining power across the value chain. After BD–Velano and Terumo–EryPharm, the combined share of the five largest vendors now exceeds fifty percent of global kit revenues, raising entry barriers for stand-alone syringe and lancet makers. Deepened scale allows acquirers to lock in polypropylene supply at multi-year contracts and accelerate portfolio rationalization, trimming overlapping SKUs while preserving top-line growth. Importantly, integration of proprietary extraction tips or sensors into established platforms enables rapid cross-selling, reinforcing customer switching costs and dampening price-based competition across diverse clinical settings worldwide today.
Financial sponsors, responsible for nearly one-third of recent transactions, view blood collection assets as resilient cash generators with defensible regulatory moats. Nonetheless, escalating price tags are driving sharper diligence on reimbursement visibility and digital readiness. Median revenue multiples have climbed to five times for targets bundling data analytics or point-of-care connectivity, while deals focused on commodity tubes still clear near two times sales. The spread underscores investors’ conviction that integrating informatics with disposables will unlock recurring software fees, raise customer lifetime value, and shield portfolios from future margin erosion.
North America maintained the highest transaction volume, buoyed by proactive blood-center consolidation and abundant private-equity dry powder. Yet Asia-Pacific is catching up quickly, particularly in China and India where hospital infrastructure expansion and emerging local champions have spurred cross-border bids from Japanese and European strategics.
Technology themes shaping the mergers and acquisitions outlook for Blood Collection Market revolve around automation, sterility, and data integration. Buyers favor cloud-connected inventory platforms, closed-loop plasma systems, and smart syringes embedding RFID; regulatory focus on vein-access safety will further accelerate tech-led deal activity in 2025.
Competitive LandscapeRecent Strategic Developments
- In April 2023, the expansion type development saw Becton, Dickinson and Company allocate USD 200,000,000 to construct an additional pre-analytical systems line at its Zaragoza, Spain facility. The larger footprint increases tube and needle production for European blood banks, shortens lead times during seasonal demand spikes and intensifies pricing pressure on regional mid-tier manufacturers that lack comparable scale.
- Haemonetics Corporation completed an acquisition of OpSens Inc. in October 2023 for USD 253,000,000. The deal integrates OpSens’ fiber-optic sensor technology into Haemonetics’ blood collection portfolio, enabling real-time venous pressure monitoring during apheresis. Competitors are now compelled to accelerate R&D around sensor-embedded devices, shifting competition from commodity consumables toward data-rich, value-added disposables.
- January 2024 witnessed a strategic investment partnership between Terumo Blood and Cell Technologies and Fresenius Kabi. Both firms committed joint funding to co-develop next-generation apheresis systems that combine Terumo’s automation software with Fresenius’ plasma collection disposables. The collaboration locks in shared intellectual property, raises barriers to entry for emerging Asian contract manufacturers and signals growing consolidation among premium technology providers.
SWOT Analysis
- Strengths: The blood collection market benefits from indispensable clinical relevance, as venous and capillary sampling underpin diagnostics, transfusion medicine and biopharmaceutical manufacturing. Global installed bases of automated phlebotomy equipment and apheresis systems create high switching costs that favor incumbent manufacturers. Regulatory bodies mandate strict sterility and traceability standards, reinforcing demand for single-use tubes, needles and lancets that drive steady, recurring revenue. Scale advantages enable leading suppliers to negotiate favorable resin and rubber contracts, protecting margins even when raw material prices fluctuate. These factors collectively sustain a positive outlook, with the sector projected to rise from USD 15.20 Billion in 2025 toward USD 23.35 Billion by 2032 at a 6.30% CAGR.
- Weaknesses: Despite robust demand, the industry faces pronounced sensitivity to resin supply disruptions, which can halt tube production and trigger hospital shortages. Product portfolios remain heavily weighted toward low-margin commodity consumables, limiting pricing leverage when group purchasing organizations negotiate bulk tenders. Phlebotomist shortages and patient needle phobia lead to sample quality issues and recollection costs that erode provider confidence. Moreover, the waste stream of plastic components attracts scrutiny from environmental regulators, compelling manufacturers to invest in costly recycling and sustainable-material initiatives that dilute near-term profitability.
- Opportunities: Emerging economies in Asia-Pacific, Latin America and Africa are scaling national blood-bank infrastructure, unlocking multi-million unit tenders for collection sets, anticoagulant tubes and rapid typing cards. Integration of RFID, near-field communication and fiber-optic sensors into collection devices enables real-time vein pressure monitoring and chain-of-custody tracking, opening premium price tiers. Home-based sampling for telehealth, genomics and decentralized clinical trials is expanding addressable volumes beyond the hospital, while point-of-care analyzers generate pull-through demand for micro-collection consumables. Strategic partnerships between device makers and plasma fractionators offer cross-selling potential into high-growth therapeutic plasma collection centers.
- Threats: Cost-containment initiatives by public health systems and insurers exert downward pressure on consumable prices, incentivizing hospitals to trial private-label imports from low-cost manufacturers. Consolidation among diagnostics conglomerates could marginalize smaller competitors by bundling collection kits with analyzers at discounted rates. Technological shifts toward non-invasive, continuous monitoring and micro-sensor patches threaten to displace traditional venipuncture for routine diagnostics. Finally, geopolitical instability can disrupt cross-border resin, steel cannula and packaging supplies, while pandemics or emerging blood-borne pathogens may trigger sudden regulatory overhauls that delay product approvals and necessitate unplanned sterilization validation investments.
Future Outlook and Predictions
The global blood collection market is poised for steady, rather than explosive, expansion over the next decade. ReportMines projects value rising from USD 15.20 Billion in 2025 to roughly USD 23.35 Billion by 2032, reflecting a resilient 6.30% compound annual growth rate. Persistently high diagnostic volumes and widening plasma-derived therapeutics pipelines underpin this positive trajectory.
Underlying demand will be reinforced by aging populations, growing chronic disease prevalence, and expanding universal health coverage in emerging economies. Governments in India, Indonesia, and Brazil are building regional blood-bank networks capable of processing millions of units annually. These infrastructure investments translate directly into larger procurement contracts for tubes, needles, and apheresis systems, stabilizing vendor order books.
Technology will shift competition from commodity disposables toward data-rich solutions. Fiber-optic pressure sensors, RFID tube labels, and analytics dashboards shorten phlebotomy cycles, reduce hemolysis rates, and feed laboratory automation pipelines. Hospitals adopting such platforms report cost avoidance, incentivizing suppliers to bundle software licenses with consumables. Consequently, R&D budgets are shifting toward electronics integration and connectivity over mechanical redesign.
Decentralized healthcare will open a parallel growth channel. Telehealth providers, direct-to-consumer genomics firms, and decentralized clinical trial sponsors are piloting capillary micro-collection kits that patients use at home and ship by courier. While unit prices exceed traditional tubes, lower logistical overhead makes the total cost per analyte attractive, encouraging payers to reimburse remote sampling for diabetes, lipid, and therapeutic drug monitoring.
Plasma-derived medicines are emerging as the fastest-growing end use, propelled by rising diagnoses of primary immunodeficiency and heightened demand for albumin in surgical recovery. To meet volume benchmarks, commercial plasma centers are expanding in the United States and opening facilities across Central Europe, necessitating thousands of next-generation apheresis stations. Manufacturers offering higher plasma yield per session will command pricing premiums and supply-chain priority.
Regulators are simultaneously tightening safety and sustainability expectations. The European Union is drafting revised Blood, Tissues, and Cells legislation that will likely require digital traceability from donor to recipient, accelerating barcode and blockchain adoption. In parallel, extended-producer-responsibility laws in Canada and Australia will link disposable-plastics fees to recycling rates, pushing vendors toward bio-based polymers and reusable transport racks to protect margins.
Competitive dynamics will favor scale, portfolio breadth, and proximity to raw materials. Dominant multinationals are expected to intensify acquisition activity, targeting regional pre-analytical kit suppliers to secure ethylene-oxide sterilization capacity and diversify geopolitical exposure. Mid-sized players lacking vertical integration may pivot toward contract manufacturing or niche innovations, yet persistent resin price volatility will make independent survival challenging beyond 2030.
Table of Contents
- Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Blood Collection Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Blood Collection by Geographic Region, 2017, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Blood Collection by Country/Region, 2017,2025 & 2032
- 2.2 Blood Collection Segment by Type
- Blood Collection Tubes
- Blood Collection Needles and Syringes
- Lancets
- Blood Collection Sets
- Blood Bags
- Capillary Blood Collection Devices
- Accessories and Ancillary Supplies
- 2.3 Blood Collection Sales by Type
- 2.3.1 Global Blood Collection Sales Market Share by Type (2017-2025)
- 2.3.2 Global Blood Collection Revenue and Market Share by Type (2017-2025)
- 2.3.3 Global Blood Collection Sale Price by Type (2017-2025)
- 2.4 Blood Collection Segment by Application
- Diagnostic Testing
- Therapeutic Transfusion
- Blood Component Collection and Processing
- Clinical Research and Clinical Trials
- Point-of-Care Testing
- Home Healthcare and Self-Collection
- 2.5 Blood Collection Sales by Application
- 2.5.1 Global Blood Collection Sale Market Share by Application (2020-2025)
- 2.5.2 Global Blood Collection Revenue and Market Share by Application (2017-2025)
- 2.5.3 Global Blood Collection Sale Price by Application (2017-2025)
Frequently Asked Questions
Find answers to common questions about this market research report
Company Intelligence
Key Companies Covered
View detailed company rankings, SWOT insights, and strategic profiles for this report.